<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821284</url>
  </required_header>
  <id_info>
    <org_study_id>20F.1207</org_study_id>
    <nct_id>NCT04821284</nct_id>
  </id_info>
  <brief_title>Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer</brief_title>
  <official_title>Optimizing Ultrasound Enhanced Delivery of Therapeutics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the effect of sonoporation in addition to standard of care&#xD;
      chemotherapy in treating patients with pancreatic cancer. Sonoporation is a novel method that&#xD;
      uses ultrasound and microbubbles to increase therapeutic effect by increasing uptake or&#xD;
      enhance sensitization. Sonoporation together with chemotherapy may work better in treating&#xD;
      patients with pancreatic cancer compared to chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Gehan-Breslow-Wilcoxon test and Log-rank (Mantel-Cox) test will be used to compare survival. All clinical variables (e.g., concomitant imaging results, blood tests, etc.) will also be compared between the groups with and without sonoporation. When both types of variables are ordinal or continuous, correlations will be calculated. Continuous data will be analyzed using t-tests, or Mann-Whitney tests.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Locally Advanced Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Metastatic Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Stage II Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IIA Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IIB Pancreatic Cancer AJCC v8</condition>
  <condition>Stage III Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IV Pancreatic Cancer AJCC v8</condition>
  <condition>Unresectable Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity. Patients also receive sonazoid IV over 20 minutes and undergo CEUS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Perflubutane Microbubble</intervention_name>
    <description>Oxaliplatin</description>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast-Enhanced Ultrasound</intervention_name>
    <description>Undergo CEUS</description>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (sonazoid, ultrasound, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be &gt;= 18 years old&#xD;
&#xD;
          -  Patient has a new diagnosis of inoperable PDAC and is scheduled to undergo SoC&#xD;
             chemotherapy (inclusion of patients with human immunodeficiency virus [HIV] or chronic&#xD;
             hepatitis B and C will be at the discretion of their treating oncologist based on&#xD;
             their ability to tolerate SoC chemotherapy)&#xD;
&#xD;
               -  (International Classification of Diseases [ICD]-10 C25.0 Malignant neoplasm: Body&#xD;
                  of pancreas, C25.2 Malignant neoplasm: Tail of pancreas and C25.3 Malignant&#xD;
                  neoplasm: Pancreatic duct)&#xD;
&#xD;
               -  Histologically verified, locally advanced (nonresectable stage II/III) or&#xD;
                  metastatic (stage IV) adenocarcinoma of the pancreas&#xD;
&#xD;
          -  The PDAC must be visible on grayscale ultrasound prior to injection of ultrasound&#xD;
             contrast&#xD;
&#xD;
          -  Must be ambulatory with an ECOG performance status between 0 and 2&#xD;
&#xD;
          -  Female patients of child-bearing potential must have a negative urine pregnancy test&#xD;
             and use (and agree to continue to use throughout the study) one of the following forms&#xD;
             of contraception from the screening Visit until completion of the first study&#xD;
             follow-up visit: hormonal (oral, implant or injection) begun &gt; 15 days prior to the&#xD;
             screening visit, barrier (e.g., condom, diaphragm with spermicide), intra-uterine&#xD;
             device or vasectomized partner (6 months minimum). Male patients must also agree to&#xD;
             practice throughout the study an approved method of birth control.&#xD;
&#xD;
             * (Note: To be considered NOT of child-bearing potential, female patients must be&#xD;
             postmenopausal [with amenorrhea for at least 2 years prior to study entry] or&#xD;
             surgically sterile [bilateral tubal ligation at least 6 months prior to study entry,&#xD;
             or of a hysterectomy and/or bilateral oophorectomy])&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL (prior to enrollment per SoC)&#xD;
&#xD;
          -  Neutrophils (polymorphonuclear leukocytes) &gt; 3.5 x 10^9/L (prior to enrollment per&#xD;
             SoC)&#xD;
&#xD;
          -  Platelets (PLT) &gt; 100 x 10^9/L (prior to enrollment per SoC)&#xD;
&#xD;
          -  Bilirubin &lt; 75 umol/L (1.5 x upper limit of normal [ULN]) (prior to enrollment per&#xD;
             SoC)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and&#xD;
             alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =&lt; 3 x ULN&#xD;
             (prior to enrollment per SoC)&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) of &gt; 1.5 x 10^9/L (1500mm^3) (prior to enrollment per&#xD;
             SoC)&#xD;
&#xD;
          -  Signed informed consent and expected cooperation of the patients for the treatment and&#xD;
             follow up must be obtained and documented according to International Conference on&#xD;
             Harmonization (ICH)/Good Clinical Practice (GCP), and national/local regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient participated in an investigational study within 7 days prior to study entry&#xD;
             (or, if longer, within five half-lives of the last dose of any investigational drug&#xD;
&#xD;
          -  Patient has severe chronic obstructive pulmonary disease, or pulmonary hypertension or&#xD;
             unstable cardiopulmonary conditions&#xD;
&#xD;
          -  Patients with pulmonary vasculitis or a history of pulmonary emboli&#xD;
&#xD;
          -  Patients who are medically unstable. For example:&#xD;
&#xD;
               -  Patients on life support or in a critical care unit&#xD;
&#xD;
               -  Patients with unstable occlusive disease (e.g., crescendo angina)&#xD;
&#xD;
               -  Patients with clinically unstable cardiac arrhythmias, such as recurrent&#xD;
                  ventricular tachycardia&#xD;
&#xD;
               -  Patients with uncontrolled congestive heart failure (New York Heart Association&#xD;
                  [NYHA] class IV)&#xD;
&#xD;
               -  Patients with recent cerebral hemorrhage&#xD;
&#xD;
               -  Patients who have undergone surgery within 24 hours prior to the study&#xD;
                  sonographic examination&#xD;
&#xD;
          -  Patient with a history of any psychiatric disorder or cognitive impairment that would&#xD;
             interfere with participation in the study in the opinion of the investigator&#xD;
&#xD;
          -  Patient requires dialysis or has severely impaired renal function, defined as a serum&#xD;
             creatinine &gt;= 1.5 x ULN or calculated creatinine clearance &lt; 45 mL/min at the&#xD;
             screening visit&#xD;
&#xD;
          -  Patient has severe impairment of liver function, defined as a serum albumin level =&lt;&#xD;
             25 g/L and/or a prothrombin time international normalized ratio (INR) &gt; 2.3 (or&#xD;
             activated partial thromboplastin time [APTT] &gt; 6 seconds above the upper limit of&#xD;
             normal) at the screening visit&#xD;
&#xD;
          -  Patients with a history of anaphylactic allergy to eggs or egg products, manifested by&#xD;
             one or more of the following symptoms: generalized urticaria, difficulty in breathing,&#xD;
             swelling of the mouth and throat, hypotension, or shock. (Subjects with non&#xD;
             anaphylactic allergies to eggs or egg products may be enrolled in the study, but must&#xD;
             be watched carefully for 1 hour following the administration of Sonazoid)&#xD;
&#xD;
          -  Patients that are allergic to any other component of Sonazoid&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not participate&#xD;
&#xD;
          -  Patients with metastatic adenocarcinoma of the pancreas who have moderate to severe&#xD;
             hepatic impairment&#xD;
&#xD;
          -  Patient is pregnant or is breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flemming Forsberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Flemming Forsberg, PhD</last_name>
    <phone>215-955-4870</phone>
    <email>flemming.forsberg@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Flemming Forsberg, PhD</last_name>
      <phone>215-955-4870</phone>
      <email>Flemming.Forsberg@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Odd Gilja</last_name>
      <phone>47 55972133</phone>
      <email>Odd.Gilja@uib.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

